Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-6145
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
INO-6145 is a synthetic consensus (SynCon®) DNA plasmid vaccine developed by Inovio Pharmaceuticals for the treatment of HIV-1 infection. It is one of two plasmid components (alongside INO-6112) that constitute the PENNVAX-GP vaccine regimen. INO-6145 utilizes codon-optimized DNA sequences to encode HIV-1 antigens, aiming to elicit robust, broad-based CD8+ T cell responses targeting conserved viral epitopes for potential HIV remission. The vaccine is typically co-administered with the DNA adjuvant INO-9012, which encodes interleukin-12 (IL-12), and is delivered via electroporation using the CELLECTRA® device to enhance cellular uptake and immunogenicity. It has reached Phase 2 clinical development for HIV-1 infections.
- Other names
- SynCon INO-6145
02
Targets
HIV (HIV-1 enzymes)
Beyond the preview
Go deeper on INO-6145.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-6145.